Skip to main content
SpringerLink
Log in

Mechanism of Action and Preclinical Profile of Raloxifene, a Selective Estrogen Receptor Modulator*

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stockard CR, Papanicolaou GN. The existence of a typical oestrous cycle in the guinea-pig with a study of its histological and physiological changes. Am J of Anat 1917;22:225-228.

    Google Scholar 

  2. Doisy EA, Veler CD, Thayer S. Folliculin from urine of pregnant women. Am J Physiol 1929;90:617-622.

    Google Scholar 

  3. Marrian GF, Butenandt A. Desirous-producing hormones. Nature 1931;128:305.

    Google Scholar 

  4. Riggs BL. Overview of osteoporosis. West J Med 1991;154:63-77.

    Google Scholar 

  5. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.

    Google Scholar 

  6. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-1041.

    Google Scholar 

  7. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study [see comments]. N Engl J Med 1991;325:756-762.

    Google Scholar 

  8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.

    Google Scholar 

  9. Munk-Jensen N, Pors Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controled study. Br Med J (Clin Res Ed) 1988;296:1150-1152.

    Google Scholar 

  10. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.

    Google Scholar 

  11. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News and Perspect 1995;8:531-539.

    Google Scholar 

  12. Sherwin BB, Tulandi T. “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri [see comments]. J Clin Endocrinol Metab 1996;81:2545-2549.

    Google Scholar 

  13. Buyon JP. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus. J Am Med Womens Assoc 1998;53:13-17.

    Google Scholar 

  14. Blevins GT Jr, Huang HS, Tangoku A, Mckay DW, Rayford PL. Estrogens influence cholecystokinin stimulated pancreatic amylase release and acinar cell membrane cholecystokinin receptors in rat. Life Sci 1991;48:1565-1574.

    Google Scholar 

  15. Sahiner T, Aktan E, Kaleli B, Oguzhanoglu A. The effects of postmenopausal hormone replacement therapy on sympathetic skin response. Maturitas 1998;30:85-88.

    Google Scholar 

  16. Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 1973;182:126-134.

    Google Scholar 

  17. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988;55:145-156.

    Google Scholar 

  18. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEES Lett 1987;210:37-39.

    Google Scholar 

  19. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol. 1997;273:L119-L126.

    Google Scholar 

  20. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen [published erratum appears in J Clin Invest 1999 May;103(9):1363]. J Clin Invest 1999;103:401-406.

    Google Scholar 

  21. Pappas TC, Gametchu B, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 1995;9:404-410.

    Google Scholar 

  22. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 1999;19:2455-2463.

    Google Scholar 

  23. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.

    Google Scholar 

  24. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEES Lett 1996;392:49-53.

    Google Scholar 

  25. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870.

    Google Scholar 

  26. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-4265.

    Google Scholar 

  27. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SL. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer. Cancer Res 1999;59:525-528.

    Google Scholar 

  28. Sar M, Welsch F. Differential expression of estrogen receptor-beta and estrogen receptor-alpha in the rat ovary. Endocrinology 1999;140:963-971.

    Google Scholar 

  29. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor beta in rat bone. Endocrinology 1997;138:4509-4512.

    Google Scholar 

  30. Grohe C, Kahlert S, Lobbert K, Vetter H. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 156:R1-R7.

  31. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 1998;64:187-191.

    Google Scholar 

  32. Mitchner NA, Garlick C, Ben-Jonathan N. Cellular distribution and gene regulation of estrogen receptors alpha and beta in the rat pituitary gland. Endocrinology 1998;139:3976-3983.

    Google Scholar 

  33. Shughrue PJ, Lane MV, Scrimo PJ, Merchenthaler I. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 1998;63:498-504.

    Google Scholar 

  34. Wilson ME, Price RH Jr, Handa RJ. Estrogen receptor-beta messenger ribonucleic acid expression in the pituitary gland. Endocrinology 1998;139:5151-5156.

    Google Scholar 

  35. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 1997;272:19858-19862.

    Google Scholar 

  36. Shibata H, Onate SA, Onate SA, Jenster G, Tsai SY, Tsai MJ, BW OM. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997;52:141-164.

    Google Scholar 

  37. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994;264:1455-1458.

    Google Scholar 

  38. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-968.

    Google Scholar 

  39. Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998;273:27645-27653.

    Google Scholar 

  40. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 1999;96:6947-6952.

    Google Scholar 

  41. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-486.

    Google Scholar 

  42. Dana SL, Hoener PA, Wheeler DA, Lawrence CB, McDonnell DP. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol Endocrinol 1994;8:1193-1207.

    Google Scholar 

  43. Yang NN. Erratum: Correction: Raloxifene response needs more than an element (Science (February 28) (1234)). Science 1997;276:21.

    Google Scholar 

  44. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [see comments] [published erratum appears in Science 1997 Feb 28;275(5304):1249]. Science 1996;273:1222-1225.

    Google Scholar 

  45. Krishnan V, Wang X, Safe S. Estrogen receptor-Spl complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 1994;269:15912-15917.

    Google Scholar 

  46. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifene activation of the estrogen receptor/AP-1 Pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-456.

    Google Scholar 

  47. Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 1997;25:2424-2429.

    Google Scholar 

  48. Hoyland JA, Mee AP, Baird P, Braidman IP, Mawer EB, Freemont AJ. Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone 1997;20:87-92.

    Google Scholar 

  49. Pan LC, Ke HZ, Simmons HA, Crawford DT, Chidsey-Frink KL, McCurdy SP, Schafer JR, Kimbro KS, Taki M, Korach KS, Thompson DD. Estrogen receptor-alpha knockout (erko) mice lose trabecular and cortical bone following ovariectomy. J Bone Miner Res 1997;12:S134.

    Google Scholar 

  50. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-15682.

    Google Scholar 

  51. Upton GV. The perimenopause: physiologic correlates and clinical management. J Reprod Med 1982;27:1-28.

    Google Scholar 

  52. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.

    Google Scholar 

  53. Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 1992;48:345-355.

    Google Scholar 

  54. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-1146.

    Google Scholar 

  55. Sato M, Bryant HU. Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro. In: Kuramoto H, Gurpide E, eds. In Vitro Biology of Sex Steroid Hormones Action. Tokyo: Churchill Livingstone, 1996:406-421.

    Google Scholar 

  56. Bryant HU, Cole HW, Adrian MD, Wilson PK, Sato M. Raloxifene and estrogen preserve PTH induced bone mass in ovariectomized rats—Experimental Biology 96, Part II. FASEB J 1996;10:A469.

    Google Scholar 

  57. Sato M, Glasebrook AL, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 1994;12:S9-S20.

    Google Scholar 

  58. Short LL, Glasebrook AL, Adrian MD, Cole H, Shetler P, Rowley ER, Magee DE, Pell T, Zeng G, Sato M, Bryant HU. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J Bone Miner Res 1996;11(1).

  59. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab 1995;14:1-9.

    Google Scholar 

  60. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-69.

    Google Scholar 

  61. Fuchs-Young R, Magee DE, Cole HW, Short LL, Glasebrook AL, Rippy MK, Termine JD, Bryant HU. Raloxifene is a tissue specific anti-estrogen that blocks tamoxifen or estrogen stimulated uterogenic effects. Endocrinology 1995;136:S37.

    Google Scholar 

  62. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.

    Google Scholar 

  63. Davies GC, Huster WJ, Shen W, Mitlak BH, Plouffe L, Shah A, Cohen FJ. The endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999;6:188-195.

    Google Scholar 

  64. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.

    Google Scholar 

  65. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001-2005.

    Google Scholar 

  66. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [see comments] [published erratum appears in N Engl J Med 1995 Jan 12;332(2):131]. N Engl J Med 1994;331:1056-1061.

    Google Scholar 

  67. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR. Raloxifene (LY139481 HCi) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-69.

    Google Scholar 

  68. Turner RT, Evans GL, Wakley GK. Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption. J Bone Miner Res 1993;8:359-366.

    Google Scholar 

  69. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10:905-912.

    Google Scholar 

  70. Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW. Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994;9:715-724.

    Google Scholar 

  71. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995;272:1252-1259.

    Google Scholar 

  72. Bryant HU, Turner CH, Frolik CA, Magee DE, Cole HW, Brown CE, Rippy MK, Sato M. Long-term effects of raloxifene on bone, cholesterol and uterus in ovariectomized rats. Bone 1995;16:116S.

    Google Scholar 

  73. Jerome CP, Lees CJ, Register TC, Stancill M. Iliac and lumbar vertebral histomorphometry, bone densitometry and bone biomarker data from raloxifene-treated macaques — ASBMR 19th Annual Meeting. J Bone Miner Res 1997;12:S347.

    Google Scholar 

  74. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.

    Google Scholar 

  75. Evans GL, Magee DE, Bryant HU, Turner RT. Raloxifene is as effective as estrogen in preventing further bone loss in mature rats with established osteoporosis. J Bone Miner Res 1994;9(Suppl. 1):S198.

    Google Scholar 

  76. Jiang Y, Zhao J, Van Audekercke R, Dequeker J, Geusens P. Effects of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties. Calcif Tissue Int 1996;58:30-39.

    Google Scholar 

  77. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone [published erratum appears in Endocr Rev 1994 April;15(2):261]. Endocr Rev 1993;14:690-709.

    Google Scholar 

  78. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994;134:2283-2288.

    Google Scholar 

  79. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996;18:621-627.

    Google Scholar 

  80. Bryant HU, Magee DE, Cole HW, Chandrasekhar S, Hsung HM, Herman ML, Sato M. Beneficial effects of ethynyl estradiol and raloxifene in the ovariectomized rat are dependent on an intact pituitary. J Bone Miner Res 1994;9:S135.

    Google Scholar 

  81. Magee DE, Cole HW, Brown CE, Bryant HU. Raloxifene and estrogen retain anti-osteopenic activity in ovariectomized (OVX) rats fed a low calcium diet. J Bone Miner Res 1994;9(Suppl. 1):S198.

    Google Scholar 

  82. Bryant HU, Black LJ, Rowley ER, Sato M, Cullinan GJ. Medroxyprogesterone augments the bone effects of estrogen or raloxifene in the ovariectomized rat. Endocrinology 1995;136:S396.

    Google Scholar 

  83. Shetler PK, Rowley ER, Cole HW, Adrian MD, Magee DE, Pell T, Sato M, Bryant HU. Raloxifene, estrogen, LY117018, and testosterone in steroid hormone deficient male rat. J Bone Miner Res 1996;11:S446-abstr T585.

    Google Scholar 

  84. Passeri G, Girasole G, Jilka RL, Manolagas SC. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 1993;133:822-828.

    Google Scholar 

  85. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257:88-91.

    Google Scholar 

  86. Glasebrook AL, Short LL, Cole HW, Magee DE, Bryant HU. Regulation of serum IL-6 by raloxifene in an OVX rat model. Bone 1995;16:68.

    Google Scholar 

  87. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJS, Glasebrook AL, Termine JD. Estrogen and raloxifene stimulate transforming growth factor-β 3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 1996;137:2075-2084.

    Google Scholar 

  88. Gize EA, Venugopalan M, Glasebrook AL, Yang NN. Characterization of raloxifene binding and transactivation properties of the estrogen receptor-beta (ERbeta)—ASBMR 19th Annual Meeting. J Bone Miner Res 1997;12:S460.

    Google Scholar 

  89. Miyaura C, Onoe Y, Inada M, Maki K, Ikuta K, Ito M, Suda T. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 1997;94:9360-9365.

    Google Scholar 

  90. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Effects of the raloxifene analog LY117018 on B-lymphopoiesis and bone loss induced by estrogen deficiency—ASBMR 19th Annual Meeting. J Bone Miner Res 1997;12:S167.

    Google Scholar 

  91. Glasebrook AL, Phillips DL, Sluka JP. Multiple binding sites for the antiestrogen raloxifene (LY156758). J Bone Miner Res 1993;8:S268.

    Google Scholar 

  92. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J-A, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-758.

    Google Scholar 

  93. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-669.

    Google Scholar 

  94. Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CWI, Martin MJ, Matsumoto K, Pennington LD, Winter MA, Adrian MD, Cole HW, Magee DE, Phillips DL, Rowley ER, Short LL, Glasebrook AL, Bryant HU. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997;40:146-167.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Research Division, Lilly Research Laboratories, Indianapolis, IN, USA

    Henry U. Bryant

Authors
  1. Henry U. Bryant
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bryant, H.U. Mechanism of Action and Preclinical Profile of Raloxifene, a Selective Estrogen Receptor Modulator*. Rev Endocr Metab Disord 2, 129–138 (2001). https://doi.org/10.1023/A:1010019410881

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010019410881

Search

Navigation